Moonlight AI Raises €2.8M to Revolutionize Cancer Diagnosis

⚡

Key Takeaways

1Moonlight AI, a Swiss startup, raises €2.8 million to develop AI-based oncology diagnostics.

2Moonlight AI's technology uses medical images to identify biomarkers without resorting to expensive genetic sequencing.

3The company is building a global database to enhance the accuracy of AI diagnostics through diverse data.

💡Why it matters — This innovation could transform access to cancer diagnostics, making care faster and less expensive.

Moonlight AI: A Promising Fundraising Round for Innovation in Oncology

The era of oncological diagnostics is undergoing a major transformation, where cutting-edge technologies are no longer limited to genetic sequencing equipment or specialized laboratories. Now, artificial intelligence (AI) models are taking center stage by enabling the extraction of crucial biological information directly from medical images. It is in this context that Moonlight AI AG, a young Swiss company, stands out. It has just announced a Seed funding round of €2.8 million, aimed at strengthening its position in image analysis for clinical diagnostics.

An Innovative Approach Combining AI and Medical Expertise

Moonlight AI was founded on a combination of expertise in hematology, pathology, and artificial intelligence. The startup develops software capable of transforming images of blood smears or cytological samples into actionable diagnostic data. The goal is to help laboratories and physicians identify certain genomic biomarkers or pathological signatures related to cancers more quickly, while avoiding the systematic use of next-generation sequencing (NGS).

Addressing the Challenges of Precision Medicine

This approach aims to overcome a major limitation of current precision medicine. Although targeted therapies increasingly rely on genetic analysis of tumors, sequencing remains a costly, complex, and often slow process in hospital settings. Moonlight AI offers an alternative solution by using computer vision to detect molecular information directly from images already integrated into daily clinical workflows.

Immediate and Actionable Results

Christian Ruiz, CEO and co-founder of Moonlight AI, explains: “Our technology allows laboratories to generate actionable and immediate results from slides they are already using in their core workflows. By eliminating the need for expensive equipment or manual processes, we empower laboratories to increase their diagnostic capacity and provide faster results to patients.”

The Rise of Digital Pathology

Technically, Moonlight AI is part of the rise of AI models applied to digital pathology. In recent years, several academic studies have demonstrated the possibility of inferring certain genetic mutations or tumor characteristics from histopathological images. Moonlight AI strives to transform these scientific advancements into a clinically usable infrastructure on a large scale.

Targeting Complex Pathologies

Currently, the startup is focusing its efforts on several pathologies with high diagnostic complexity, such as myelodysplastic syndromes (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia. Part of the raised funds will also be used to accelerate regulatory work and the commercialization of the developed solutions.

A Proprietary Database as a Strategic Asset

One of the main strategic assets of Moonlight AI lies in its proprietary database. The company is building a library that combines cytopathological imaging and genomic data, with the ambition of creating one of the first datasets of its kind on an international scale. In the field of medical AI, the quality and diversity of data are crucial for training models and their future clinical validation.

An International Consortium to Enrich Data

Nicole H. Romano, CTO and co-founder of Moonlight AI, specifies: “By collaborating with an international consortium of clinical partners, we are creating a dataset designed to ensure the robustness of models in real laboratory environments and among diverse patient populations.”

A Call for International Collaboration

The startup is also looking to expand this consortium to increase the clinical and geographical diversity of the data used to train its models. Dr. Stefan Habringer, Chief Medical Officer and co-founder of Moonlight AI, emphasizes: “The success of AI-based diagnostics fundamentally depends on the quality and diversity of clinical data. Therefore, we are opening our consortium to other hospitals and laboratories wishing to contribute to shaping the next generation of diagnostics.”

A Funding Round Supported by Renowned Investors

The funding round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with participation from N&V Capital as well as historical investor QAI Ventures.